IVZ therapy increases treatment-free interval in nonresponsive eyes with nAMD
Use of intravitreal ziv-aflibercept (IVZ) therapy improves treatment-free interval in eyes with neovascular age-related macular degeneration (nAMD) that are nonresponsive to bevacizumab and ranibizumab, a recent study has shown. However, no significant change in visual and anatomic outcomes has been observed.
IVZ therapy provided no change in the mean logarithm of minimum angle of resolution (logMAR) best corrected visual acuity (BCVA) at baseline and following treatment (p=0.978). Mean IVZ injections during 12 months was 5.9±3.3, and the mean number of antivascular endothelial growth factors (VEGFs) injections prior to switching to IVZ was 8.4±4.7.
Mean treatment-free interval was longer during IVZ therapy compared with days prior to IVZ therapy (114.4±67.1 vs 76.3±54.6 days; p=0.03). Visual gains of at least 0.1 logMAR were achieved in five eyes (31.25 percent), while three eyes (18.75 percent) had stable BCVA (within 0.1 logMAR) and eight eyes (50 percent) had BCVA decline of at least 0.1 logMAR.
Mean changes in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, and presence of subretinal (SRF) and intraretinal fluid (IRF) were not significant at 12 months vs baseline. Additionally, there were no adverse events reported.
Researchers included 16 eyes of 14 patients with nAMD who were on prior treatment with bevacizumab and ranibizumab in this retrospective study. All eyes were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months.
The mean change in BCVA was the primary outcome measure, and secondary outcome measures included mean change in CMT, RPED heights, longest treatment-free interval, presence of SRF and IRF, and adverse events.